Ariad's potential blockbuster Iclusig gets early FDA OK

After fast-tracking it, the FDA approved Ariad Pharmaceuticals' ($ARIA) closely watched leukemia drug ponatinib today, a product that analysts say could generate blockbuster sales. The FDA said Iclusig, as it is branded, was being approved three months early under its program that gives priority review to drugs where no alternative exists. That is good news for patients and Ariad. Ariad CEO Harvey Berger has said that the drug could bring annual sales of $800 million for patients for whom  previous treatments have failed and hit $1.5 billion with the additional use against new cases. Story | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.